SG174585A1 - Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved - Google Patents

Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved Download PDF

Info

Publication number
SG174585A1
SG174585A1 SG2011069937A SG2011069937A SG174585A1 SG 174585 A1 SG174585 A1 SG 174585A1 SG 2011069937 A SG2011069937 A SG 2011069937A SG 2011069937 A SG2011069937 A SG 2011069937A SG 174585 A1 SG174585 A1 SG 174585A1
Authority
SG
Singapore
Prior art keywords
formula
compound
salt
preparing
base
Prior art date
Application number
SG2011069937A
Other languages
English (en)
Inventor
Richard Polniaszek
Steven Pfeiffer
Richard Yu
Aaron Cullen
Eric Dowdy
Duong Tran
Kenneth Kent
Zhongxin Zhou
Doug Cordeau
Leah Easton
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42634770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG174585(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of SG174585A1 publication Critical patent/SG174585A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/68—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
    • C07C209/70—Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton by reduction of unsaturated amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/34—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfuric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG2011069937A 2009-04-03 2010-04-01 Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved SG174585A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16649809P 2009-04-03 2009-04-03
PCT/US2010/029633 WO2010115000A2 (en) 2009-04-03 2010-04-01 Methods and intermediates for preparing pharmaceutical agents

Publications (1)

Publication Number Publication Date
SG174585A1 true SG174585A1 (en) 2011-10-28

Family

ID=42634770

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2011069937A SG174585A1 (en) 2009-04-03 2010-04-01 Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved
SG10201404926UA SG10201404926UA (en) 2009-04-03 2010-04-01 Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201404926UA SG10201404926UA (en) 2009-04-03 2010-04-01 Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved

Country Status (27)

Country Link
US (4) US8497396B2 (enExample)
EP (2) EP2414325B1 (enExample)
JP (8) JP5612662B2 (enExample)
KR (3) KR20180077324A (enExample)
CN (4) CN104876888B (enExample)
AP (1) AP2887A (enExample)
AR (1) AR076027A1 (enExample)
AU (1) AU2010232559B2 (enExample)
BR (1) BRPI1012638B8 (enExample)
CA (4) CA2925137C (enExample)
CL (1) CL2011002370A1 (enExample)
CO (1) CO6400216A2 (enExample)
EA (2) EA201590979A1 (enExample)
EC (1) ECSP11011391A (enExample)
ES (1) ES2548252T3 (enExample)
HK (1) HK1223912A1 (enExample)
IL (4) IL215399A (enExample)
MX (2) MX2011010397A (enExample)
NZ (4) NZ617773A (enExample)
PE (1) PE20120617A1 (enExample)
PT (1) PT2414325E (enExample)
SG (2) SG174585A1 (enExample)
TW (2) TW201518283A (enExample)
UA (1) UA108738C2 (enExample)
UY (1) UY32535A (enExample)
WO (1) WO2010115000A2 (enExample)
ZA (1) ZA201107430B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108738C2 (uk) 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
JP2012140390A (ja) * 2011-01-06 2012-07-26 Sumitomo Chemical Co Ltd α−アミノ−γ−ブチロラクトンの製造方法
ES2543923T3 (es) * 2011-05-02 2015-08-25 Gilead Sciences, Inc. Sales sólidas amorfas de Cobicistat (GS-9350)
MX2014009344A (es) * 2012-02-03 2015-05-11 Gilead Sciences Inc Metodos e intermediarios para preparar agentes farmaceuticos.
WO2014047849A1 (zh) * 2012-09-27 2014-04-03 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
CN103694196A (zh) * 2012-09-27 2014-04-02 上海迪赛诺化学制药有限公司 细胞色素p450单加氧酶抑制剂中间体及其制法和用途
WO2014057498A2 (en) 2012-10-08 2014-04-17 Mylan Laboratories Ltd. Process for the preparation of cobicistat intermediates
WO2014105777A1 (en) * 2012-12-26 2014-07-03 Assia Chemical Industries Ltd. Cobicostat dichlohydrate salt
CN104370777A (zh) * 2013-08-13 2015-02-25 上海迪赛诺化学制药有限公司 合成(2r,5r)-1,6-二苯基己烷-2,5-二胺及其盐的中间体及所述中间体的制备方法和应用
JP2016538312A (ja) * 2013-11-29 2016-12-08 マイラン ラボラトリーズ リミテッドMylan Laboratories Limited 非晶質のコビシスタットの固体分散体
EP3077373B1 (en) 2013-12-03 2018-09-12 Mylan Laboratories Ltd. Preparation of cobicistat intermediates
CN104193643B (zh) * 2014-09-12 2016-02-10 宁波九胜创新医药科技有限公司 用于合成抗艾滋病药物增强剂cobicistat的中间体
CN104447472A (zh) * 2014-11-06 2015-03-25 江苏森萱医药化工股份有限公司 D)-2-苄基-n,n-二甲基氮杂环丙烷基-1-磺酰胺合成方法
CN104557565B (zh) * 2015-01-08 2016-07-06 浙江工业大学 抗艾滋病药物增强剂Cobicistat关键中间体盐酸盐的制备方法
US10454867B2 (en) * 2015-02-09 2019-10-22 Airwatch Llc Enhanced e-mail delivery to mobile devices
US10351556B2 (en) * 2015-02-18 2019-07-16 Msn Laboratories Private Limited Process for the preparation of 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2s)-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4YL] methyl} carbamoyl) amino]-4-(morpholin-4-yl)butanoyl]amino)-1,6-diphenylhexan-2-yl]carbamate
CN107674039A (zh) * 2016-08-01 2018-02-09 上海朴颐化学科技有限公司 一种可比西他中间体的制备方法
US20180085387A1 (en) 2016-09-27 2018-03-29 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
CN109912530A (zh) * 2017-12-13 2019-06-21 上海奥博生物医药技术有限公司 一种可比司他原料杂质的制备方法
CN109232301B (zh) * 2018-10-15 2021-01-01 天津希恩思生化科技有限公司 一种四异丙基肼的制备方法
CN110642721B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 盐酸司来吉兰的制备方法
CN110878071A (zh) * 2019-11-21 2020-03-13 华南农业大学 一种α-氨基-γ-丁内酯及其盐的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1183026E (pt) * 1999-06-04 2006-11-30 Abbott Lab Formulações farmacêuticas melhoradas incluindo ritonavir
US20030153771A1 (en) 2001-09-27 2003-08-14 Kolb Hartmuth C. Large scale synthesis of optically pure aziridines
WO2003106445A1 (en) * 2002-06-12 2003-12-24 Qsi Pharma A/S Compounds and methods for controlling bacterial virulence
EP1771536A1 (en) * 2004-07-23 2007-04-11 The Procter and Gamble Company Liquid detergent composition for improved low temperature grease cleaning and starch soil cleaning
US7786153B2 (en) * 2005-03-02 2010-08-31 Abbott Laboratories Inc. Compounds that are useful for improving pharmacokinetics
KR101477822B1 (ko) * 2006-07-07 2015-01-02 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학 특성의 모듈레이터
PT3150586T (pt) * 2007-02-23 2020-03-31 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
KR20100040896A (ko) * 2007-07-06 2010-04-21 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학적 특성의 조절제
PT2231628E (pt) * 2008-01-04 2015-12-29 Gilead Sciences Inc Inibidores de citocromo p450
EA201591353A1 (ru) 2008-05-02 2016-01-29 Джилид Сайэнс, Инк. Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
UA108738C2 (uk) 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки

Also Published As

Publication number Publication date
JP6491706B2 (ja) 2019-03-27
NZ708978A (en) 2017-01-27
US9428473B2 (en) 2016-08-30
HK1223912A1 (en) 2017-08-11
TWI464165B (zh) 2014-12-11
MX338731B (es) 2016-04-28
IL237643A (en) 2017-01-31
ECSP11011391A (es) 2012-03-30
TW201518283A (zh) 2015-05-16
IL237642A0 (en) 2015-04-30
JP2020189861A (ja) 2020-11-26
IL250068A0 (en) 2017-03-30
WO2010115000A3 (en) 2011-09-22
EA201590979A1 (ru) 2016-02-29
CA3083433A1 (en) 2010-10-07
KR20120006035A (ko) 2012-01-17
ES2548252T3 (es) 2015-10-15
US8497396B2 (en) 2013-07-30
AU2010232559B2 (en) 2015-06-18
US20140088304A1 (en) 2014-03-27
CN104876888B (zh) 2018-06-15
CL2011002370A1 (es) 2012-05-25
CA2925137C (en) 2018-07-31
US8853210B2 (en) 2014-10-07
JP2018162274A (ja) 2018-10-18
HK1214265A1 (zh) 2016-07-22
JP6336161B2 (ja) 2018-06-06
EA201190179A1 (ru) 2013-01-30
PE20120617A1 (es) 2012-05-26
CN111217808A (zh) 2020-06-02
US20100256366A1 (en) 2010-10-07
EP2414325B1 (en) 2015-08-26
US20150005493A1 (en) 2015-01-01
CN102438982A (zh) 2012-05-02
US20160002186A1 (en) 2016-01-07
NZ594864A (en) 2014-03-28
ZA201107430B (en) 2012-12-27
WO2010115000A2 (en) 2010-10-07
AU2010232559A1 (en) 2011-10-06
NZ726536A (en) 2018-04-27
CA2925137A1 (en) 2010-10-07
EP2414325A2 (en) 2012-02-08
NZ617773A (en) 2016-02-26
CA2754698C (en) 2016-06-07
IL237643A0 (en) 2015-04-30
KR20180077324A (ko) 2018-07-06
BRPI1012638B8 (pt) 2021-05-25
JP6180561B2 (ja) 2017-08-16
CA2754698A1 (en) 2010-10-07
CN107382997A (zh) 2017-11-24
SG10201404926UA (en) 2015-02-27
BRPI1012638A2 (pt) 2016-04-05
AP2011005864A0 (en) 2011-10-31
JP2014193897A (ja) 2014-10-09
TW201100412A (en) 2011-01-01
KR20170043672A (ko) 2017-04-21
CA3008903A1 (en) 2010-10-07
JP5986599B2 (ja) 2016-09-06
UA108738C2 (uk) 2015-06-10
UY32535A (es) 2010-10-29
EP3009434A1 (en) 2016-04-20
JP2023002679A (ja) 2023-01-10
MX2011010397A (es) 2011-10-24
CA3008903C (en) 2021-06-08
HK1166976A1 (zh) 2012-11-16
CN107382997B (zh) 2021-02-26
JP2017122107A (ja) 2017-07-13
CO6400216A2 (es) 2012-03-15
KR101874557B1 (ko) 2018-07-04
KR101728375B1 (ko) 2017-04-19
PT2414325E (pt) 2015-10-29
IL215399A0 (en) 2011-12-29
IL215399A (en) 2015-11-30
CN104876888A (zh) 2015-09-02
JP5612662B2 (ja) 2014-10-22
US9115100B2 (en) 2015-08-25
AU2010232559A8 (en) 2011-11-10
AR076027A1 (es) 2011-05-11
JP2012522797A (ja) 2012-09-27
HK1245785A1 (zh) 2018-08-31
CN102438982B (zh) 2015-05-06
JP2018008983A (ja) 2018-01-18
IL237642A (en) 2017-01-31
JP2016128476A (ja) 2016-07-14
BRPI1012638B1 (pt) 2021-04-20
AP2887A (en) 2014-05-31
CA3083433C (en) 2022-08-09
EA022739B1 (ru) 2016-02-29

Similar Documents

Publication Publication Date Title
AU2010232559B2 (en) Method of preparing an inhibitor of cytochrome P450 monooxygenase, and intermediates involved
WO2012045007A1 (en) Method of preparation of (4 - {4 -acetylamino- 2 - [3- ( 2 - isopropyl - thiazol - 4 - ylmethyl) - 3 -methyl - ureido] - butyryl amino} -1 -benzyl- 5 -phenyl- pentyl) -carbamic acid thiazol - 5 - ylmethyl ester
HK1166976B (en) Method of preparing an inhibitor of cytochrome p450 monooxygenase, and intermediates involved